WebJan 9, 2024 · 1. Introduction. Multiple myeloma (MM), which accounts for 10–15% of all hematologic malignancies, arises from a terminally differentiated postgerminal center plasma cells in the bone marrow (BM) and is characterized by a monoclonal proliferation of plasma cells resulting in the production of monoclonal antibodies and end-organ damage … WebFeb 11, 2024 · The advent of novel therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, has led to unprecedented levels of deep hematologic responses. Nonetheless, studies show that ASCT has an additive effect leading to additional deepening of responses.
Novel drug shows promising efficacy for patients with multiple myeloma …
Web1 day ago · OM-301 has received an orphan drug designation from the FDA for the treatment of patients with multiple myeloma, according to Oncolyze. 1. OM-301 is an investigational … WebMar 20, 2024 · Patients who received two or more novel agents (usually as triplets), like bortezomib plus lenalidomide and dexamethasone (VRD), or patients treated with … diamond fire spark plugs review
Novel lenalidomide-based combinations for treatment of multiple myeloma
WebMultiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art Massimo Martino Annalisa Paviglianiti Mara Memoli Giovanni Martinelli Claudio … WebHowever, patients who relapse after treatment with these agents or are refractory to them represent an unmet need and highlight the necessity for the development of novel anti … WebAug 19, 2024 · The addition of novel agents and combinations to the treatment of multiple myeloma, along with improvements in personalized therapy based on genetic profiles of … diamond firetail birdlife